Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAID BEYDOUN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Clinical Neurophysiology

NPI
1700827482
CMS profile
77490
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$161,380.25

154 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ARGENX US, INC. $31,300.37 30
Alexion Pharmaceuticals, Inc. $28,783.23 17
UCB, Inc. $24,842.32 29
Takeda Pharmaceuticals U.S.A., Inc. $16,561.55 18
Alnylam Pharmaceuticals Inc. $16,047.77 16
Amylyx Pharmaceuticals, Inc. $15,395.44 18
CSL Behring $14,880.57 11
AstraZeneca Pharmaceuticals LP $4,512.67 5
Grifols USA, LLC $4,026.47 3
Genentech, Inc. $3,828.03 3
MITSUBISHI TANABE PHARMA AMERICA, INC. $1,100.00 1
Octapharma USA, Inc. $100.17 1
Travere Therapeutics, Inc. $1.66 2

Page 2 of 4; records 51–100 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAID BEYDOUN

NPI 1700827482 · CMS profile ID 77490

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Clinical Neurophysiology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700827482?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAID BEYDOUN, NPI 1700827482, CMS profile ID 77490. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700827482?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SAID BEYDOUN, NPI 1700827482, CMS profile ID 77490. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700827482?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SAID BEYDOUN, NPI 1700827482, CMS profile ID 77490, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1700827482?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

154 matching records · $161,380.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 154 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 154.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARGENX US, INC. $8,625.0008/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398699 CMS
ARGENX US, INC. $62.4808/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398703 CMS
ARGENX US, INC. $39.3008/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398711 CMS
UCB, Inc. $80.2507/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021787267 CMS
UCB, Inc. $126.6607/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053866915 CMS
UCB, Inc. $253.4907/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021787313 CMS
UCB, Inc. $287.8007/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021787317 CMS
UCB, Inc. $439.9007/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021787325 CMS
UCB, Inc. $183.1207/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053866911 CMS
Alnylam Pharmaceuticals Inc. $121.8607/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006133525 CMS
ARGENX US, INC. $215.4607/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398701 CMS
ARGENX US, INC. $34.1207/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398705 CMS
ARGENX US, INC. $48.7607/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398707 CMS
ARGENX US, INC. $14.6107/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398717 CMS
ARGENX US, INC. $14.6107/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398719 CMS
ARGENX US, INC. $545.9807/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398709 CMS
Takeda Pharmaceuticals U.S.A., Inc. $618.7507/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055349793 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,392.1907/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055349789 CMS
CSL Behring $3,820.1907/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042902843 CMS
UCB, Inc. $60.0007/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021787261 CMS
Alnylam Pharmaceuticals Inc. $1,030.0007/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006133467 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,093.7506/26/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055349785 CMS
ARGENX US, INC. $1,150.0006/21/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398689 CMS
Amylyx Pharmaceuticals, Inc. $778.0705/19/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057674897 CMS
ARGENX US, INC. $3,450.0005/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398691 CMS
Takeda Pharmaceuticals U.S.A., Inc. $182.2605/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055349777 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6,875.0005/16/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055349781 CMS
AstraZeneca Pharmaceuticals LP $2,148.0005/15/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015420641 CMS
Travere Therapeutics, Inc. $0.8305/10/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059600083 CMS
ARGENX US, INC. $277.1505/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398675 CMS
ARGENX US, INC. $80.0005/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398677 CMS
ARGENX US, INC. $237.9605/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398679 CMS
ARGENX US, INC. $563.1905/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398681 CMS
ARGENX US, INC. $588.1905/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398683 CMS
Alexion Pharmaceuticals, Inc. $4,720.0005/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016975553 CMS
Alnylam Pharmaceuticals Inc. $4,635.0005/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006133491 CMS
Alnylam Pharmaceuticals Inc. $84.5805/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006133497 CMS
Travere Therapeutics, Inc. $0.8305/02/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059600077 CMS
ARGENX US, INC. $2,300.0004/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060398667 CMS
Alexion Pharmaceuticals, Inc. $31.1904/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017005351 CMS
Amylyx Pharmaceuticals, Inc. $2,625.0004/26/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057674885 CMS
Amylyx Pharmaceuticals, Inc. $2,625.0004/26/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057674891 CMS
UCB, Inc. $120.9004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021787287 CMS
Takeda Pharmaceuticals U.S.A., Inc. $66.6704/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055349773 CMS
AstraZeneca Pharmaceuticals LP $129.6004/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011726321 CMS
AstraZeneca Pharmaceuticals LP $24.0704/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015778439 CMS
Amylyx Pharmaceuticals, Inc. $95.6904/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057674881 CMS
Amylyx Pharmaceuticals, Inc. $180.2704/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057674869 CMS
Amylyx Pharmaceuticals, Inc. $597.8004/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057674873 CMS
Amylyx Pharmaceuticals, Inc. $2,362.5004/21/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057674877 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $166,803.95 185
PY2020 $91,614.10 67
PY2021 $57,535.13 52
PY2022 $118,158.88 97
PY2023 $161,380.25 154
PY2024 $203,751.19 175
PY2025 $186,245.93 160

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $225,481.06 24
PY2024 Principal investigator $148,553.41 85
PY2023 Principal investigator $341,284.78 49
PY2022 Recipient $780.00 1
PY2022 Principal investigator $191,334.64 29
PY2021 Recipient $3,200.00 1
PY2021 Principal investigator $250,284.72 35
PY2020 Recipient $1,270.00 2
PY2020 Principal investigator $150,545.70 19
PY2019 Principal investigator $165,036.43 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $2,200.00 10/27/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226142860
Principal investigator 1 SANOFI US SERVICES INC. $2,950.00 10/06/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226142849
Principal investigator 1 Novartis Pharmaceuticals Corporation $301.12 10/02/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190306749
Principal investigator 1 SANOFI US SERVICES INC. $1,850.00 06/23/2025 Non-covered Recipient Entity
University Of Southern California
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226140241
Principal investigator 1 SANOFI US SERVICES INC. $2,150.00 06/23/2025 Non-covered Recipient Entity
University Of Southern California
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226140245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 06/18/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184207969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 06/18/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184208095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,986.53 05/29/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200263
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 05/27/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226142795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184194037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184194039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184194041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184194043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 05/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184194045
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,616.68 05/01/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190304501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $891.81 04/25/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184190147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,726.51 04/25/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184190149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,867.40 03/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184176834
Principal investigator 1 SANOFI US SERVICES INC. $8,450.00 03/17/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226142694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,783.62 02/17/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184154130
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,599.45 01/31/2025 Non-covered Recipient Entity
KECK SCHOOL OF MEDICINE
A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS) No dispute reported 06/30/2026 1190307925
Principal investigator 1 SANOFI US SERVICES INC. $11,050.00 01/21/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226142698
Principal investigator 1 UCB SA $7,964.38 01/15/2025 Non-covered Recipient Entity
University Of Southern California
Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1246657278
Principal investigator 1 Novartis Pharmaceuticals Corporation $132,693.56 01/01/2025 Non-covered Recipient Entity
KECK SCHOOL OF MEDICINE
A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS) No dispute reported 06/30/2026 1190307927